Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Waters Corporation (WAT) CEO Christopher O'Connell on Q1 2019 Results - Earnings Call Transcript

Weaker-than-expected first-quarter earnings results caused the specialty measurement company's stock to slide.

Why Waters Corporation Shares Are Sinking Today

Shares of Waters Corporation plunged Tuesday after the medical supplier's first-quarter revenue and earnings widely lagged Wall Street estimates.

This Medical Supplier Toppled Below A Breakout On Its Earnings Lag

Waters' (WAT) first-quarter 2019 results were negatively impacted by sluggish customer spending and macro-economic headwinds.

Waters' (WAT) Earnings and Revenues Miss Estimates in Q1

Waters (WAT) delivered earnings and revenue surprises of -7.51% and -5.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q1 Earnings and Revenues Miss Estimates

Waters' (WAT) first-quarter results are likely to benefit from its well performing segments and end-market momentum.

Waters (WAT) to Report Q1 Earnings: What's in the Cards?

News for Waters Stock (WAT)